Recurring Consumables RevenueThe company earns recurring revenue from disposables and leasing, which creates a predictable, repeatable revenue stream tied to procedure volume. Over months this supports unit economics and aftermarket margins, aiding cash generation if installed base and procedure rates stabilize.

High Gross MarginAn 84.1% gross margin indicates attractive product-level economics and pricing power for the Cellvizio platform and consumables. This durable margin profile provides room to absorb operating costs and scale profitably if revenue growth resumes and fixed-cost leverage improves.

Proprietary Imaging TechnologyCellvizio's real-time cellular imaging is a specialized technology with applications in gastroenterology, pulmonology and oncology. This niche, clinically integrated device and associated consumables create barriers to entry and durable competitive positioning among diagnostic imaging solutions.

Bears Say

Significant Revenue DeclineA 30.6% year-over-year revenue drop materially weakens scale and the installed-base economics that underpin consumable sales. Prolonged top-line contraction can erode pricing leverage, limit margin recovery, and impede investment in commercialization over the next several quarters.

Negative Equity / Balance Sheet RiskThe balance sheet shows negative equity with total liabilities exceeding assets, signaling elevated solvency and leverage risk. This structural weakness constrains financing options, increases refinancing dilution risk, and may force restructuring if cash needs persist over the medium term.

Persistent Negative Cash FlowOperating and free cash flows are negative despite slight free-cash-flow improvement, indicating the company is burning cash to operate. Sustained negative cash generation requires external funding, which can dilute shareholders or curtail R&D and commercialization investments over months.

ALMKT FAQ

What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?

MAUNA KEA TECHNOLOGIES lowest stock price was €0.06 and its highest was €0.19 in the past 12 months.

What is MAUNA KEA TECHNOLOGIES’s market cap?

MAUNA KEA TECHNOLOGIES’s market cap is €24.17M.

When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?

MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Apr 09, 2026 which is in 50 days.

How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?

MAUNA KEA TECHNOLOGIES released its earnings results on Oct 01, 2025. The company reported -€0.068 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.068.

Is MAUNA KEA TECHNOLOGIES overvalued?

According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MAUNA KEA TECHNOLOGIES pay dividends?

MAUNA KEA TECHNOLOGIES does not currently pay dividends.

What is MAUNA KEA TECHNOLOGIES’s EPS estimate?

MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MAUNA KEA TECHNOLOGIES have?

MAUNA KEA TECHNOLOGIES has 192,097,270 shares outstanding.

What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?

MAUNA KEA TECHNOLOGIES reported an EPS of -€0.068 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?

Currently, no hedge funds are holding shares in FR:ALMKT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

MAUNA KEA TECHNOLOGIES

Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions. The company was incorporated in 2000 and is headquartered in Paris, France.